{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T06:13:47Z","timestamp":1772518427508,"version":"3.50.1"},"reference-count":34,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2008,5,1]],"date-time":"2008-05-01T00:00:00Z","timestamp":1209600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,5,1]],"date-time":"2008-05-01T00:00:00Z","timestamp":1209600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2008,5,1]],"date-time":"2008-05-01T00:00:00Z","timestamp":1209600000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2008,5,1]],"date-time":"2008-05-01T00:00:00Z","timestamp":1209600000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2008,5,1]],"date-time":"2008-05-01T00:00:00Z","timestamp":1209600000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2008,5,1]],"date-time":"2008-05-01T00:00:00Z","timestamp":1209600000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2008,5,1]],"date-time":"2008-05-01T00:00:00Z","timestamp":1209600000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2008,5]]},"DOI":"10.1016\/j.atherosclerosis.2007.10.012","type":"journal-article","created":{"date-parts":[[2007,12,6]],"date-time":"2007-12-06T11:36:33Z","timestamp":1196940993000},"page":"77-84","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Inhibition of intestinal absorption of cholesterol by ezetimibe or bile acids by SC-435 alters lipoprotein metabolism and extends the lifespan of SR-BI\/apoE double knockout mice"],"prefix":"10.1016","volume":"198","author":[{"given":"Anne","family":"Braun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayce","family":"Yesilaltay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Acton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kay O.","family":"Broschat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elaine S.","family":"Krul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nida","family":"Napawan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy","family":"Stagliano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monty","family":"Krieger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2007.10.012_bib1","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1210\/jcem.87.2.8057","article-title":"Clinical review 141: lipids and atherosclerosis: lessons learned from randomized controlled trials of lipid lowering and other relevant studies","volume":"87","author":"Kreisberg","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.atherosclerosis.2007.10.012_bib2","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1517\/13543784.15.11.1337","article-title":"Cholesterol absorption inhibitors as a therapeutic option for hypercholesterolaemia","volume":"15","author":"Burnett","year":"2006","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.atherosclerosis.2007.10.012_bib3","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0022-3565(24)36992-7","article-title":"In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461","volume":"283","author":"van Heek","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.atherosclerosis.2007.10.012_bib4","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1021\/jm970701f","article-title":"Discovery of 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4-hydroxyphenyl)-2-azetidinone (SCH 58235): a designed, potent, orally active inhibitor of cholesterol absorption","volume":"41","author":"Rosenblum","year":"1998","journal-title":"J Med Chem"},{"key":"10.1016\/j.atherosclerosis.2007.10.012_bib5","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1517\/14728222.10.6.851","article-title":"Non-low-density lipoprotein cholesterol-associated actions of ezetimibe: an overview","volume":"10","author":"Gazi","year":"2006","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.atherosclerosis.2007.10.012_bib6","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1053\/meta.2001.26737","article-title":"The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs","volume":"50","author":"Davis","year":"2001","journal-title":"Metabolism"},{"key":"10.1016\/j.atherosclerosis.2007.10.012_bib7","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1161\/hq1201.100260","article-title":"Ezetimibe, a potent cholesterol absorption inhibitor, inhibits the development of atherosclerosis in apoE knockout mice","volume":"21","author":"Davis","year":"2001","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2007.10.012_bib8","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0014-2999(01)00825-1","article-title":"The cholesterol absorption inhibitor, ezetimibe, decreases diet-induced hypercholesterolemia in monkeys","volume":"415","author":"van Heek","year":"2001","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.atherosclerosis.2007.10.012_bib9","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.2337\/diabetes.50.6.1330","article-title":"Ezetimibe, a potent cholesterol absorption inhibitor, normalizes combined dyslipidemia in obese hyperinsulinemic hamsters","volume":"50","author":"van Heek","year":"2001","journal-title":"Diabetes"},{"key":"10.1016\/j.atherosclerosis.2007.10.012_bib10","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1194\/jlr.M400475-JLR200","article-title":"Delineation of molecular changes in intrahepatic cholesterol metabolism resulting from diminished cholesterol absorption","volume":"46","author":"Repa","year":"2005","journal-title":"J Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2007.10.012_bib11","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ahj.2004.06.024","volume":"149","author":"Kastelein","year":"2005","journal-title":"Am Heart J"},{"key":"10.1016\/j.atherosclerosis.2007.10.012_bib12","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1161\/01.ATV.0000257627.40486.46","article-title":"Deficiency of Niemann-Pick C1 Like 1 prevents atherosclerosis in apoE\u2212\/\u2212 mice","volume":"27","author":"Davis","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2007.10.012_bib13","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/01.smj.0000208120.73327.db","article-title":"Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review","volume":"99","author":"Insull","year":"2006","journal-title":"South Med J"},{"key":"10.1016\/j.atherosclerosis.2007.10.012_bib14","series-title":"Proceedings of the XIV International Symposium on Drugs Affecting Lipid Metabolism","article-title":"SC-435 is a potent inhibitor of the apical sodium co-dependent bile acid transporter (ASBT) in mice, rats, hamsters and dogs and reduces atherosclerotic lesions in apoE \u2212\/\u2212 mice","author":"Rapp","year":"2001"},{"key":"10.1016\/j.atherosclerosis.2007.10.012_bib15","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1124\/jpet.102.038711","volume":"303","author":"West","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.atherosclerosis.2007.10.012_bib16","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1161\/01.ATV.0000035390.87288.26","article-title":"Inhibition of the apical sodium-dependent bile acid transporter reduces LDL cholesterol and apoB by enhanced plasma clearance of LDL apoB","volume":"22","author":"Huff","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2007.10.012_bib17","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1194\/jlr.M200469-JLR200","article-title":"Inhibition of ileal bile acid transport and reduced atherosclerosis in apoE\u2212\/\u2212 mice by SC-435","volume":"44","author":"Bhat","year":"2003","journal-title":"J Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2007.10.012_bib18","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.atherosclerosis.2003.08.019","article-title":"SC-435, an ileal apical sodium co-dependent bile acid transporter (ASBT) inhibitor lowers plasma cholesterol and reduces atherosclerosis in guinea pigs","volume":"171","author":"West","year":"2003","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2007.10.012_bib19","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.metabol.2004.01.017","article-title":"Inhibition of ileal bile acid transport lowers plasma cholesterol levels by inactivating hepatic farnesoid X receptor and stimulating cholesterol 7 alpha-hydroxylase","volume":"53","author":"Li","year":"2004","journal-title":"Metabolism"},{"key":"10.1016\/j.atherosclerosis.2007.10.012_bib20","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1126\/science.1411543","article-title":"Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E","volume":"258","author":"Zhang","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.atherosclerosis.2007.10.012_bib21","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0092-8674(92)90362-G","article-title":"Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells","volume":"71","author":"Plump","year":"1992","journal-title":"Cell"},{"key":"10.1016\/j.atherosclerosis.2007.10.012_bib22","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1161\/hh0302.104462","article-title":"Loss of SR-BI expression leads to the early onset of occlusive atherosclerotic coronary artery disease, spontaneous myocardial infarctions, severe cardiac dysfunction, and premature death in apolipoprotein E-deficient mice","volume":"90","author":"Braun","year":"2002","journal-title":"Circ Res"},{"key":"10.1016\/j.atherosclerosis.2007.10.012_bib23","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1161\/CIRCULATIONAHA.104.523563","article-title":"Diet-induced occlusive coronary atherosclerosis, myocardial infarction, cardiac dysfunction, and premature death in scavenger receptor class B type I-deficient, hypomorphic apolipoprotein ER61 mice","volume":"111","author":"Zhang","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2007.10.012_bib24","doi-asserted-by":"crossref","first-page":"9322","DOI":"10.1073\/pnas.96.16.9322","article-title":"Influence of the high density lipoprotein receptor SR-BI on reproductive and cardiovascular pathophysiology","volume":"96","author":"Trigatti","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.atherosclerosis.2007.10.012_bib25","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1161\/01.ATV.0000158310.64498.ac","article-title":"Lymphocytes are not required for the rapid onset of coronary heart disease in scavenger receptor class B type I\/apolipoprotein E double knockout mice","volume":"25","author":"Karackattu","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2007.10.012_bib26","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1172\/JCI13288","article-title":"Abnormal lipoprotein metabolism and reversible female infertility in HDL receptor (SR-BI)-deficient mice","volume":"108","author":"Miettinen","year":"2001","journal-title":"J Clin Invest"},{"key":"10.1016\/j.atherosclerosis.2007.10.012_bib27","doi-asserted-by":"crossref","first-page":"7283","DOI":"10.1073\/pnas.1237725100","article-title":"Probucol prevents early coronary heart disease and death in the high-density lipoprotein receptor SR-BI\/apolipoprotein E double knockout mouse","volume":"100","author":"Braun","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.atherosclerosis.2007.10.012_bib28","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1194\/jlr.M200482-JLR200","article-title":"Inhibition of both the apical sodium-dependent bile acid transporter and HMG-CoA reductase markedly enhances the clearance of LDL apoB","volume":"44","author":"Telford","year":"2003","journal-title":"J Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2007.10.012_bib29","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1161\/01.ATV.0000202662.63876.02","article-title":"Hepatic lipase deficiency delays atherosclerosis, myocardial infarction, and cardiac dysfunction and extends lifespan in SR-BI\/apolipoprotein E double knockout mice","volume":"26","author":"Karackattu","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2007.10.012_bib30","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1146\/annurev.physiol.65.092101.142243","article-title":"Cardiac hypertrophy: the good, the bad, and the ugly","volume":"65","author":"Frey","year":"2003","journal-title":"Annu Rev Physiol"},{"key":"10.1016\/j.atherosclerosis.2007.10.012_bib31","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1182\/blood.V99.5.1817.h8001817_1817_1824","article-title":"Failure of red blood cell maturation in mice with defects in the high-density lipoprotein receptor SR-BI","volume":"99","author":"Holm","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.atherosclerosis.2007.10.012_bib32","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1161\/01.CIR.0000142610.10530.25","article-title":"Probucol protects against smooth muscle cell proliferation by upregulating heme oxygenase-1","volume":"110","author":"Deng","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2007.10.012_bib33","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1084\/jem.20060218","article-title":"Lipoprotein oxidation in cardiovascular disease: chief culprit or innocent bystander?","volume":"203","author":"Heinecke","year":"2006","journal-title":"J Exp Med"},{"key":"10.1016\/j.atherosclerosis.2007.10.012_bib34","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/00041433-200108000-00002","article-title":"Cholesteryl ester transfer protein, high-density lipoprotein and arterial disease","volume":"12","author":"Barter","year":"2001","journal-title":"Curr Opin Lipidol"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915007006648?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915007006648?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:30:52Z","timestamp":1758155452000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915007006648"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,5]]}},"alternative-id":["S0021915007006648"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2007.10.012","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2008,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibition of intestinal absorption of cholesterol by ezetimibe or bile acids by SC-435 alters lipoprotein metabolism and extends the lifespan of SR-BI\/apoE double knockout mice","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2007.10.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}